Tumor Biology

, Volume 36, Issue 3, pp 1755–1762 | Cite as

MicroRNAs used as novel biomarkers for detecting cancer metastasis

  • Chunshan Han
  • Haixiang Yu
  • Lening Zhang
  • Xiaoli Li
  • Yonggang Feng
  • Hua Xin
Research Article

Abstract

The low survival rates of cancers are primarily due to late diagnosis and metastasis. Discriminating the metastasis is a crucial factor for prognosis and improving the survival rate of cancer patients. MicroRNAs (miRNAs) can regulate the expression of hundreds of downstream genes, which has a broad effect on the regulation of the whole cell cycle. Accumulating studies have found that the aberrant expression of miRNAs is associated with cancer genesis. The aim of this study is to evaluate the diagnostic value of miRNAs in detecting cancer metastasis. Medline, PubMed, Embase, and CNKI were searched for relevant articles. Sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR) and diagnostic odds ratio (DOR), the summary receiver operator characteristic (SROC) curve and the calculated AUC (area under the SROC curve) were applied to explore the diagnostic accuracy of miRNAs in metastasis. Seven hundred seventy-one metastatic cancer patients and 552 non-metastatic cancer controls from 14 articles were involved in our meta-analysis. A sensitivity of 0.75 (95 % confidence interval (CI), 0.72–0.79) and a specificity of 0.80 (95 % CI, 0.76–0.84) were observed from metastatic patients and non-metastatic controls in the combined analysis. And the AUC was 0.83 (95 % CI, 0.79–0.86). In addition, results from subgroup analyses suggested that a higher diagnostic value for metastasis was acquired in tissue sample other than blood sample (sensitivity, 0.82 versus 0.73; specificity, 0.84 versus 0.79; PLR, 5.0 versus 3.5; NLR, 0.22 versus 0.34; DOR, 23 versus 10; AUC, 0.88 versus 0.80). In summary, this meta-analysis proved the relatively high diagnostic value of miRNA in metastasis, which might be applied as a novel screening tool to detect metastasis along with other biomarkers. We also illustrated that tissue-based miRNAs may have a better diagnostic accuracy than blood-based miRNAs.

Keywords

microRNA Tissue Blood Metastasis Cancer Screening Meta-analysis 

Notes

Conflicts of interest

None

Supplementary material

13277_2014_2777_MOESM1_ESM.doc (64 kb)
Supplements S1 PRISMA Checklist. (DOC 64 kb)

References

  1. 1.
    DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.CrossRefPubMedGoogle Scholar
  2. 2.
    Wang Q, Wu X, Wu T, Li GM, Shi Y. Clinical significance of RKIP mRNA expression in non-small cell lung cancer. Tumour Biol. 2014;35:4377–80.CrossRefPubMedGoogle Scholar
  3. 3.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One. 2012;7:14.Google Scholar
  5. 5.
    Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:5.CrossRefGoogle Scholar
  6. 6.
    Metindir J, Bilir DG. Evaluation of prognostic significance in extracapsular spread of pelvic lymph node metastasis in patients with cervical cancer. Eur J Gynaecol Oncol. 2008;29:476–8.PubMedGoogle Scholar
  7. 7.
    Biewenga P, van der Velden J, Mol BW, Stalpers LJ, Schilthuis MS, van der Steeg JW, et al. Prognostic model for survival in patients with early stage cervical cancer. Cancer. 2011;117:768–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Lowery AJ, Walsh S, McDermott EW, Prichard RS. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist. 2013;18:391–407.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen J, Yao D, Li Y, Chen H, He C, Ding N, et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 2013;32:557–67. doi: 10.3892/ijmm.2013.1424.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Chen JY, Yao DS, He CJ, Lu Y. [Relationship between serum miR-21 and lymph node metastasis in cervical cancer]. J Xi’an Jiaotong Univ (Med Sci). 2012;33:351–5.Google Scholar
  11. 11.
    Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 2014;31:1863–70. doi: 10.3892/or.2014.3004.PubMedGoogle Scholar
  12. 12.
    Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 2013;34:455–62. doi: 10.1007/s13277-012-0570-5.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen YX, Ma CL, Chen ZF, Zhang W. Clinical significance of miR-143 expression in women with cervical cancer of Uyghur and Han ethnicities, in Xinjiang. Zhonghua Liu Xing Bing Xue Za Zhi. 2013;34:1120–4.PubMedGoogle Scholar
  14. 14.
    Feng L, Pang Z, Sha S, Wu B, Xu F, Yin SP. The value of diagnosis and prognosis prediction of serum mi-29a for colorectal cancer. Chin J Clin Oncol Rehabil. 2013;20:1313–5.Google Scholar
  15. 15.
    Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012;7:e33762. doi: 10.1371/journal.pone.0033762.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kim SY, Jeon TY, Choi CI, Kim DH, Kim GH, Ryu DY, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn. 2013;15:661–9. doi: 10.1016/j.jmoldx.2013.04.004.CrossRefPubMedGoogle Scholar
  17. 17.
    Lu J, Xu X, Liu X, Peng Y, Zhang B, Wang L, et al. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. Br J Cancer. 2014;110:392–8. doi: 10.1038/bjc.2013.751.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012;36:e61–7. doi: 10.1016/j.canep.2011.05.002.CrossRefPubMedGoogle Scholar
  19. 19.
    Wu WY, Xue XY, Chen ZJ, Han SL, Huang YP, Zhang LF, et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. World J Gastroenterol. 2011;17:3645–51. doi: 10.3748/wjg.v17.i31.3645.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yin J, Bai Z, Song J, Yang Y, Wang J, Han W, et al. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin J Cancer Res. 2014;26:95–103. doi: 10.3978/j.issn. 1000-9604.2014.02.07.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhao FL, Hu GD, Wang XF, Zhang XH, Zhang YK, Yu ZS. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 2012;40:859–66.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhao S, Yao D, Chen J, Ding N. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomark. 2013;17:631–6. doi: 10.1089/gtmb.2013.0085.CrossRefGoogle Scholar
  23. 23.
    Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009;34:881–95.PubMedGoogle Scholar
  24. 24.
    Xu X, Yang X, Ru G, Wu Y, Zhang S, Xing C, et al. miR-146a gene polymorphism rs2910164 and the risk of digestive tumors: a meta-analysis of 21 case-control studies. Oncol Rep. 2014;31:472–9. doi: 10.3892/or.2013.2854.PubMedGoogle Scholar
  25. 25.
    Wan D, Gu W, Xu G, Shen C, Ding D, Shen S, et al. Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis. Clin Transl Oncol. 2014. doi: 10.1007/s12094-013-1150-x.Google Scholar
  26. 26.
    Li YJ, Zhang ZY, Mao YY, Jin MJ, Jing FY, Ye ZH, et al. A genetic variant in MiR-146a modifies digestive system cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:145–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Hua HB, Yan TT, Sun QM. miRNA polymorphisms and risk of gastric cancer in Asian population. World J Gastroenterol. 2014;20:5700–7. doi: 10.3748/wjg.v20.i19.5700.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hu Y, Yu CY, Wang JL, Guan J, Chen HY, Fang JY. MicroRNA sequence polymorphisms and the risk of different types of cancer. Sci Rep. 2014;4:3648. doi: 10.1038/srep03648.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010;18:181–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Rahim F, Hajizamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S, et al. Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res. 2014;405920:23.Google Scholar
  31. 31.
    Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, et al. Identification of miRs-143 and −145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011;6:27.Google Scholar
  33. 33.
    Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 2012;28:1831–7.PubMedGoogle Scholar
  34. 34.
    Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, Zhang SL, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl. 2013;15:231–5.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10:202–10.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Chunshan Han
    • 1
  • Haixiang Yu
    • 1
  • Lening Zhang
    • 1
  • Xiaoli Li
    • 2
  • Yonggang Feng
    • 1
  • Hua Xin
    • 1
  1. 1.Department of Thoracic SurgeryChina-Japan Union Hospital of Jilin UniversityChangchunChina
  2. 2.Pharmaceutical DepartmentChina-Japan Union Hospital of Jilin UniversityChangchunChina

Personalised recommendations